This study assesses feasibility and safety, the primary outcomes, of MRI guided transurethral high intensity focused ultrasound (HIFU) ablation for prostate diseases (PD). We will enrol 10 patients to each group with criteria as follows: localised prostate cancer (PC); locally advanced PC; locally recurrent PC after external beam radiation therapy (EBRT); benign prostatic hyperplasia (BPH). Secondary outcomes are both oncologic and functional outcomes and imaging based follow up after HIFU therapy will be also assessed.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Evaluate targeting accuracy of HIFU ablation separately in each study arm/group.
Timeframe: The date of HIFU treatment
Evaluate targeting accuracy volume of HIFU ablation separately in each study arm/group.
Timeframe: The date of HIFU treatment
Radiologically determined treatment accuracy of HIFU ablation in localised PC arm/group.
Timeframe: 3-4 weeks from the treatment date
Histopathologically determined treatment accuracy of HIFU ablation in localised PC arm/group.
Timeframe: 3-4 weeks from the treatment date
Radiologically determined treatment accuracy of HIFU ablation in locally advanced PC arm/group.
Timeframe: 12 months from the treatment date
Radiologically determined treatment accuracy of HIFU ablation in locally recurrent PC after EBRT arm/group.
Timeframe: 12 months from the treatment date
Radiologically determined treatment accuracy of HIFU ablation in BPH arm/group.
Timeframe: 12 months from the treatment date
Safety of MRI guided transurethral HIFU ablation in various prostate diseases
Timeframe: 12 months from the treatment date